scholarly article | Q13442814 |
P356 | DOI | 10.1002/14651858.CD010288.PUB3 |
P698 | PubMed publication ID | 26545165 |
P2093 | author name string | Kana R Jat | |
Anju Khairwa | |||
Dinesh K Walia | |||
P2860 | cites work | Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. | Q52932526 |
Allergic Bronchopulmonary Aspergillosis | Q57749833 | ||
Prevalence of allergic bronchopulmonary aspergillosis and atopy in adult patients with cystic fibrosis | Q71434514 | ||
Inhibition of allergic reactions with antibodies to IgE | Q71883063 | ||
The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects | Q73442941 | ||
Allergic bronchopulmonary aspergillosis in Italian cystic fibrosis patients: prevalence and percentage of positive tests in the employed diagnostic criteria | Q73738269 | ||
Allergic bronchopulmonary aspergillosis | Q81875615 | ||
Steroid dependency despite omalizumab treatment of ABPA in cystic fibrosis | Q84632181 | ||
Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis | Q24187765 | ||
Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis | Q24198057 | ||
Omalizumab for asthma in adults and children | Q24201145 | ||
The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics | Q24561800 | ||
Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report | Q24657948 | ||
Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference | Q28207287 | ||
Allergic bronchopulmonary aspergillosis | Q28213702 | ||
Cystic fibrosis | Q28250200 | ||
Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis | Q28268973 | ||
Allergic bronchopulmonary aspergillosis in cystic fibrosis: role of atopy and response to itraconazole | Q33535204 | ||
Omalizumab for exacerbations of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis | Q34532536 | ||
Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis | Q34773652 | ||
Lymphocytes in allergic bronchopulmonary aspergillosis | Q35109519 | ||
Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody | Q36225592 | ||
Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics. Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis | Q44219144 | ||
Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma | Q44841358 | ||
Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab). | Q46246417 | ||
Prevalence of allergic bronchopulmonary aspergillosis in cystic fibrosis in an area with a high frequency of atopy | Q47785343 | ||
Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Epidemiologic Registry of Cystic Fibrosis. | Q52164439 | ||
P921 | main subject | cystic fibrosis | Q178194 |
aspergillosis | Q259626 | ||
allergic bronchopulmonary aspergillosis | Q1430844 | ||
P577 | publication date | 2015-11-04 | |
P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
P1476 | title | Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis |
Q87631539 | Allergic Bronchopulmonary Aspergillosis |
Q39282119 | Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. |
Q47146658 | An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases. |
Q53275447 | Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. |
Q40108783 | Fungal Pathogens in CF Airways: Leave or Treat? |
Q55396588 | Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. |
Q28073074 | Personalized Medicine in Allergy |
Search more.